Contáctenos
Acerca de la compañía
Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.
US
Desconocido
Desconocido
Empresa no verificada
Transparencia empresarial
- No verificó la información de la empresa
- Pide reseñas a sus clientes
- No respondió a las críticas negativas.